Giuseppe
Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full text: (LINK). Abstract, edited.]
------
Tigecycline Displays In Vivo Bactericidal Activity against ESBL<SUP>+</SUP> Enterobacteriaceae after 72 hour Exposure Period
Pamela R. Tessier and David P. Nicolau
Author Affiliations: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT
ABSTRACT
Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over three days against an extended spectrum β-lactamase (ESBL)-producing Escherichia coli and an ESBL-producing Klebsiella pneumoniae. Bacterial density reduction approximated 3 log<SUB>10</SUB> approaching bactericidal activity at 72h. This level of activity has not been previously noted for compounds such as tetracyclines, normally considered bacteriostatic antimicrobials. Extended regimen studies in vivo may aid in better delineation of antimicrobial effects producing improved correlation with clinical outcomes.
FOOTNOTES
Corresponding author: D. P. Nicolau, PharmD, FCCP, FIDSA, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. Tel. 860-545-3941, Fax 860-545-3992. dnicola@harthosp.org
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-Author Affiliations: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT
ABSTRACT
Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over three days against an extended spectrum β-lactamase (ESBL)-producing Escherichia coli and an ESBL-producing Klebsiella pneumoniae. Bacterial density reduction approximated 3 log<SUB>10</SUB> approaching bactericidal activity at 72h. This level of activity has not been previously noted for compounds such as tetracyclines, normally considered bacteriostatic antimicrobials. Extended regimen studies in vivo may aid in better delineation of antimicrobial effects producing improved correlation with clinical outcomes.
FOOTNOTES
Corresponding author: D. P. Nicolau, PharmD, FCCP, FIDSA, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. Tel. 860-545-3941, Fax 860-545-3992. dnicola@harthosp.org
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
------